Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1355-1359

  Miyashiro, Michael J ^a   Lo, Samuel C ^b   Stewart, Jeanette A ^c   Stewart, William C ^c  

^a Ludwig Ophthalmology Centre   (United States)

^b Private Practice   (United States)

^c University of South Carolina   (United States)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Prostaglandin analog; Travoprost

Indexed keywords

BENZALKONIUM CHLORIDE; LATANOPROST; TRAVOPROST;

AGED; ARTICLE; ASIAN AMERICAN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE DISEASE; EYE REDNESS; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; JAPANESE; MALE; MULTICENTER STUDY; OCULAR SURFACE DISEASE INDEX QUESTIONNAIRE; OPEN ANGLE GLAUCOMA; OPEN STUDY; QUESTIONNAIRE; TEAR FILM; VISUAL ACUITY;

EID: 78650686619     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S13460     Document Type: Article

References (20)

1. Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009;25(2):113-119.
2. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205-215.
3. de Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40(3): 619-630.
4. Debbasch C, Pisella PJ, de Saint JM, Rat P, Warnet JM, Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001;42(11):2525-2533.
5. Sosne G, Albeiruti AR, Hollis B, Siddiqi A, Ellenberg D, Kurpakus-Wheater M. Thymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitro. Exp Eye Res. 2006;83(3):502-507.
6. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23(4):511-519.
7. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48(9):4123-4128.
8. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27(3):339-343.
9. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther. 2008;25(8): 743-751.
10. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3: 291-295.
11. Nagai N, Murao T, Okamoto N, Ito Y. Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. J Oleo Sci. 2010;59(3):135-141.
12. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000; 118(5):615-621.
13. Walt JG, Rowe MM, Stern KL. Evaluating the functional impact of dry eye: The Ocular Surface Disease Index. Drug Inf J. 1997;31:1436.
14. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19(4):572-579.
15. Epstein SP, Chen D, Asbell PA. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009;25(5):415-424.
16. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618-621.
17. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res. 2004;78(3):379-388.
18. Netland PA, Landry T, Sullivan EK, et al; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with openangle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4): 472-484.
19. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688-703.
20. Stewart WC, Kolker AE, Stewart JA, Leech J, Jackson AL. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol. 2003;135(3): 314-320.